Small Pharma’s depressive disorder therapy trial meets primary goal

Small Pharma has reported that the Phase IIa clinical trial of intravenous (IV) N, N-Dimethyltryptamine (DMT), SPL026, in major depressive disorder (MDD) has met its primary endpoint.